Sirnaomics

Sirnaomics is a company that is known for developing clinical-stage bio-pharmaceuticals and therapeutics for life-threatening diseases. The company was founded by Patrick Y. Lu in 2007, in Washington DC, Virginia, United States.

The focus of Sirnaomics is to created RNAi therapuetics that are able to treat critical diseases such as cancer or fibrosis diseases. Developing novel siRNA-based therapeutics through their proprietary algorithm for sequencing predictions allows them to treat against specific gene targets and identify siRNAs for use against non-drugable targets.

Treatments that Sirnaomics has created and are within their pipeline include therapeutics for oncology, anti-fibrosis, anti-viral, and galahead diseases. For oncology, treating non-melanoma skin cancer, liver cancer, bladder cancer, liver cancer, colon cancer, breast cancer, and multiple cancers remain their primary focus. Hypertrophic scar reduction, keloid scarless healing, liver fibrosis (both PSC and NASH), and lung fibrosis all have anti-fibrosis solutions or treaments under development. The viral diseases the company is compiling a solution for include influenza and the coronavirus. For galahead diseases, they are finding treatments for anticoagulant therapy, dyslipidemia and metabolic disease, as well as liver fibrosis.